|
| Index | - | P/E | - | EPS (ttm) | -4.05 | Insider Own | 0.32% | Shs Outstand | 2.89M | Perf Week | 8.73% |
| Market Cap | 32.30M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | - | Perf Month | -21.71% |
| Income | -11.00M | PEG | - | EPS next Q | - | Inst Own | 5.80% | Short Float | - | Perf Quarter | -52.76% |
| Sales | - | P/S | - | EPS this Y | 69.10% | Inst Trans | 12.04% | Short Ratio | 0.11 | Perf Half Y | -1.83% |
| Book/sh | 2.68 | P/B | 1.53 | EPS next Y | - | ROA | -81.00% | Target Price | - | Perf Year | -16.46% |
| Cash/sh | 0.84 | P/C | 4.89 | EPS next 5Y | - | ROE | -91.80% | 52W Range | 3.00 - 16.02 | Perf YTD | -22.16% |
| Dividend | - | P/FCF | - | EPS past 5Y | 54.40% | ROI | - | 52W High | -74.34% | Beta | 1.78 |
| Dividend % | - | Quick Ratio | 8.60 | Sales past 5Y | - | Gross Margin | - | 52W Low | 36.97% | ATR | 0.46 |
| Employees | 5 | Current Ratio | 8.60 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 40.76 | Volatility | 8.39% 11.13% |
| Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 85.80% | Profit Margin | - | Rel Volume | 0.44 | Prev Close | 3.93 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 1.34M | Price | 4.11 |
| Recom | - | SMA20 | 6.59% | SMA50 | -38.28% | SMA200 | -32.82% | Volume | 587,896 | Change | 4.58% |
 | ||||||||||
| ||||||||||
|
||||||||||
| ||||||||||
| Leading BioSciences, Inc. develops therapeutics to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. The company was founded in 2005 and is based in Carlsbad, California. | ||||||||||
| ||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite